NucleicAI Welcomes Douglas Voet as Principal Engineering Architect to Boost AI-Driven Genomics NucleicAI has appointed Douglas Voet as Principal Engineering Architect, enhancing their AI-driven genomics and health intelligence capabilities for national-scale initiatives.

NucleicAI Welcomes Douglas Voet as Principal Engineering Architect to Boost AI-Driven Genomics #USA #Boston #NucleicAI #AI_Genomics #Douglas_Voet

Variant Bio Unveils Inference: A Revolutionary AI Genomic Drug Discovery Platform Variant Bio has launched Inference, the groundbreaking AI-powered genomic drug discovery platform, enhancing pharmaceutical research capabilities globally.

Variant Bio Unveils Inference: A Revolutionary AI Genomic Drug Discovery Platform #USA #Seattle #Drug_Discovery #Variant_Bio #AI_Genomics